<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775940</url>
  </required_header>
  <id_info>
    <org_study_id>FDASU-Rec ID021701</org_study_id>
    <nct_id>NCT04775940</nct_id>
  </id_info>
  <brief_title>Use of Perforated Barrier Membranes and IPRF Nano- Micro Sticky Bone</brief_title>
  <official_title>The Use of Perforated Barrier Membranes and IPRF Nano- Micro Sticky Bone in Horizontal Alveolar Ridge Augmentation - Controlled Clinical and Histomorphometric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing amount of horizontal bone gain 4 months after alveolar ridge augmentation using&#xD;
      IPRF Nano- micro Sticky Bone with perforated collagen membrane versus occlusive barrier&#xD;
      membrane by :&#xD;
&#xD;
        1. clinical and Radiographic analysis .&#xD;
&#xD;
        2. Histomorphometric analysis .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Horizontal alveolar bone width in mm</measure>
    <time_frame>6 months</time_frame>
    <description>Measured By Bone caliber and Cone Beam Computed Tomography (CBCT)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Bone Augmentation</condition>
  <arm_group>
    <arm_group_label>Perforated collagen membrane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Occlusive collagen membrane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Perforated collagen membrane</intervention_name>
    <description>Horizontal Bone Augmentation using Perforated Collagen Membrane</description>
    <arm_group_label>Perforated collagen membrane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Occlusive collagen membrane</intervention_name>
    <description>Occlusive collagen membrane</description>
    <arm_group_label>Occlusive collagen membrane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult patients.&#xD;
&#xD;
          2. Both sex, males and females. 3-Age from 20 - 40 years old. 4-All patients will be free&#xD;
             from any systemic diseases as evidenced by Burkett's oral medicine health history&#xD;
             questionnaire.&#xD;
&#xD;
        5-Remaining alveolar bone ≥ 8mm vertically and ≤ 4 mm horizontally. 6-Gingival biotype&#xD;
        1-2mm thickness.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Smokers.&#xD;
&#xD;
          2. Pregnant and breast feeding females.&#xD;
&#xD;
          3. Mentally retarded Patients.&#xD;
&#xD;
          4. Presence of hematologic disease.&#xD;
&#xD;
          5. Previous radiation, chemotherapy, or immunosuppressive treatments.&#xD;
&#xD;
          6. Diabetes mellitus, metabolic bone disease, ongoing treatment with bisphosphonates&#xD;
             drugs, or pregnancy.&#xD;
&#xD;
          7. Anticoagulant drugs, Endocarditis risk factors, renal and hepatic failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

